Title: Continuous Glucose Monitor

Policy #: Rx.01.218

Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs). Individual member benefits must be verified.

This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. This Pharmacy Policy will be regularly updated as scientific and medical literature becomes available. This information may include new FDA-approved indications, withdrawals, or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Intent:
The intent of this policy is to communicate the medical necessity criteria for Continuous Glucose Monitors (Dexcom®, Medtronic®) as provided under the member’s prescription drug benefit.

Description:
The Continuous Glucose Monitors (CGMs) are indicated for use in individuals with type 1 diabetes who require insulin and need to be monitored for unexplained glycemic fluctuations and hypoglycemic unawareness. Hypoglycemic unawareness is the inability of an individual to notice and recognize symptoms of hypoglycemia while they are experiencing them.

CGMs devices are considered an adjunct to be used with a traditional blood glucose monitor. These adjunctive devices allow individuals to track glucose levels and detect episodes of high and low blood sugar in real-time on an ongoing basis. The device consists of a disposable subcutaneous sensor, an external transmitter, and an external receiver (monitor), which can be a stand-alone device or built into an insulin pump. Sensors are worn as indicated by the device manufacturer in accordance with US Food and Drug Administration (FDA) labeling and are replaced on an ongoing basis.

Depending on the device sensor longevity capability, a CGMs sensor measures interstitial glucose levels for 6 to 14 days. Use of this device requires the glucose sensor to be implanted subcutaneously, usually in the abdomen or in an area above the buttocks. The transmitter is connected to the sensor by an adhesive patch, and glucose signals are sent from the sensor to the receiver every five minutes. Interstitial glucose values appear on the receiver or mobile device, where they can be read and reviewed by the individual. This data may be stored and downloaded for analysis. CGMs devices also allow for customization of threshold settings, such as alarms, to detect high and low glucose levels.

The FDA has approved several CGMs devices to assist in analyzing glycemic trends in the ongoing evaluation and management of individuals with diabetes. The FDA requires that alterations to an individual's insulin dosage or therapy are made only after confirmation of blood glucose levels with a traditional blood glucose monitor.

Policy:
Dexcom® and Medtronic® products (receivers, transmitters and sensors) are approved when ONE of the following is met:

1. Member is pregnant with a diagnosis of type 1 diabetes mellitus; OR
2. Member has type I diabetes mellitus or type 2 insulin-dependent diabetes mellitus and ALL of the following:
   a. Prescribed by or in consultation with an endocrinologist; AND
   b. Documentation that the member requires ≥ 3 insulin injections per day OR documentation that the member utilizes an insulin pump; AND
   c. The member has a documented history of poorly controlled diabetes (i.e., severe ketosis or hypoglycemic episodes without experiencing warning and recognition of symptoms or hypoglycemic unawareness); AND
d. The member demonstrates an understanding of the fundamentals of diabetes self-management including regular testing of blood glucose levels ≥ 3 times per day; AND

e. Documentation of accurate blood glucose testing records; AND

f. The member has received diabetes self-management education and instruction on utilizing Continuous Glucose Monitoring Systems (CGMs) including basic care of the CGMs (e.g., insertion, calibration, expectations), use of real-time CGM application in diabetic care, and alarm use and problem solving

Authorization duration: 2 years.

**Black Box Warning as shown in the drug Prescribing Information:**
None

**Guidelines:**
Refer to the specific manufacturer's prescribing information for administration and dosage details and any applicable Black Box warnings.

**BENEFIT APPLICATION**

Subject to the terms and conditions of the applicable benefit contract, the applicable drug(s) identified in this policy is (are) covered under the prescription drug benefits of the Company’s products when the medical necessity criteria listed in this pharmacy policy are met. Any services that are experimental/investigational or cosmetic are benefit contract exclusions for all products of the Company.

**References:**


**Applicable Drugs:**

Inclusion of a drug in this table does not imply coverage. Eligibility, benefits, limitations, exclusions, precertification/referral requirements, provider contracts, and Company policies apply.

**Dexcom® line of products**
- Dexcom® G4 Platinum Pediatric Receivers
- Dexcom® G4 Platinum Receivers
- Dexcom® G5 Mobile Receivers
- Dexcom® G6 Receivers
- Dexcom® G4 Platinum Sensors
- Dexcom® G4 Sensors
- Dexcom® G5 Mobile Sensors
- Dexcom® G6 Sensors
- Dexcom® G4 Platinum Transmitter Kit
- Dexcom® G5 Platinum Transmitter Kit

**Medtronic® line of products**
- Guardian™ Connect Transmitter
- Guardian™ Sensor
- Enlite® Sensor
Dexcom® G6 Platinum Transmitter Kit

**Cross References:**
Rx.01.33 Off-Label Use

<table>
<thead>
<tr>
<th>Policy Version Number:</th>
<th>2.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>P&amp;T Approval Date:</td>
<td>October 8, 2020</td>
</tr>
<tr>
<td>Policy Effective Date:</td>
<td>January 1, 2021</td>
</tr>
<tr>
<td>Next Required Review Date:</td>
<td>October 8, 2021</td>
</tr>
</tbody>
</table>

The Policy Bulletins on this web site were developed to assist the Company in administering the provisions of the respective benefit programs, and do not constitute a contract. If you have coverage through the Company, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. Company does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of the Company. If you have a specific medical condition, please consult with your doctor. The Company reserves the right at any time to change or update its Policy Bulletins.